Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mochida Pharmaceutical Co Ltd Obtains Manufacturing and Marketing Permission

Friday, 28 Dec 2012 01:00am EST 

Mochida Pharmaceutical Co Ltd announced that it has obtained the manufacturing and marketing permission for its treatment aiming hyperlipidemia and arteriosclerosis obliterans, as switch Over The Counter (OTC) drug, on December 28, 2012. 

Company Quote

-30.0 -0.47%
24 Oct 2014